The study — part of the USC-based, global ENIGMA Consortium — looks at brain aging and Alzheimer’s to identify predictive markers, better understand prognoses and support personalized risk evaluations.
Ishwar Puri, USC senior vice president for research and innovation, discusses some of the past year’s major accomplishments and what might be in store for 2023 and beyond.
AI-powered analysis developed at USC accurately reflects risk of cognitive decline and Alzheimer’s disease based on brain age.
The buildup of a protein called amyloid beta in the brain, often thought to be connected to Alzheimer’s, may instead be a general change that occurs with age even in healthy brains, USC’s Caleb Finch says.
Lab-made antibodies are increasingly important in the fight against Alzheimer’s, COVID and other diseases
The National Institute on Aging awarded Keck School of Medicine of USC researchers $3.7 million to explore the link between diabetes and brain health in the understudied group.
Short cycles of a low-calorie diet that replicates fasting appeared to reduce inflammation and delay cognitive decline in mouse models of Alzheimer’s disease.
A mutation in a microprotein is connected to a significant increase in the risk for Alzheimer’s and highlights a possible target for treatment, a USC Leonard Davis School of Gerontology study finds.
Researchers at USC explored the link between sedentary behavior and risk of dementia, find that type of activity matters when it comes to brain aging.
Participants who gave away more money scored significantly lower on cognitive tests known to be sensitive to Alzheimer’s disease than those who gave less, a USC study finds.
Grant from the National Institute on Aging will fund research on the role that blood vessel dysfunction plays in the development of dementia and Alzheimer’s disease.
The findings could provide potential targets for new Alzheimer’s drugs.
Research adds to evidence that healthier pre-industrial lifestyles may hold clues to preventing Alzheimer’s and other dementias.
By studying the APOE4 gene and its impact on brain inflammation and metabolism of fatty acids, Hussein Yassine discovers potential new ways to prevent cognitive decline.
After watching his twin brother lose a 15-year fight with the memory-robbing illness, Dan Epstein decided to do something about it. The result: an unprecedented research collaboration between USC and UC San Diego.
Among older Americans surveyed in the weeks after FDA approval of aducanumab, few could correctly answer true or false questions about the first new Alzheimer’s drug in decades.
A transformative donation from the Epstein Family Foundation will accelerate Alzheimer’s research at the two universities in a push to find better treatments and a cure.
Year in review: Whether they’re working with patients, test tubes or massive databases, USC scientists continue to push the envelope with discoveries that are literally changing people’s lives.
Mouse study of human stroke medication reveals potential defense against Alzheimer’s disease and other forms of dementia.
Studying neural stem cells could shed light on how environmental aspects interact with genetic risk factors for dementia, says University Professor Caleb Finch.
The psychiatry and neuroscience chair at the Keck School of Medicine of USC and director of the California Alzheimer’s Disease Center at USC discusses the role of medication in Alzheimer’s treatment.
Researchers say their studies on air pollution and cognitive decline — one involving humans and one with mice — provide evidence that cleaner air may reduce risk for Alzheimer’s and other dementias.
More assistance is needed for the estimated 11 million people caring for loved ones with dementia, USC experts say.
More than 90 federal grants totaling $92 million were awarded to USC researchers in 2020, underscoring the university’s status as one of the nation’s leading research centers as we acknowledge World Alzheimer’s Day 2021.